351P Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial

Autor: Bianchini, G., Jimenez, M. Martin, Graff, S., Jeselsohn, R., Wander, S., Layman, R., Hurvitz, S.A., Hamilton, E.P., Sammons, S., Kaufman, P., Knoderer, H., Nguyen, B., Zhou, Y., Ravenberg, E., Litchfield, L., Kalinsky, K.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S362-S363

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.

Autor: Kalinsky K; Winship Cancer Institute at Emory University, Atlanta, GA, USA., Bianchini G; IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy., Hamilton E; Sarah Cannon Research Institute, Nashville, TN, USA., Graff SL; Brown University Health, Legorreta Cancer Center at Brown University, Providence, RI, USA., Park KH; Korea University Anam Hospital, Korea University, Seoul, South Korea., Jeselsohn R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Demirci U; Memorial Ankara Hospital, Ankara, Turkey., Martin M; Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain., Layman RM; MD Anderson Cancer Center, University of Texas, Houston, TX, USA., Hurvitz SA; Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, WA, USA., Sammons S; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Kaufman PA; University of Vermont Medical Center, Burlington, VT, USA., Muñoz M; Hospital Clinic and Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomediques Pi I Sunyer-IDIBAPS, Barcelona, Spain., Lai JI; Taipei Veterans General Hospital, Taipei, Taiwan., Knoderer H; Eli Lilly and Company, Indianapolis, IN, USA., Sandoval C; Eli Lilly and Company, Indianapolis, IN, USA., Chawla AR; Eli Lilly and Company, Indianapolis, IN, USA., Nguyen B; Eli Lilly and Company, Indianapolis, IN, USA., Zhou Y; Eli Lilly and Company, Indianapolis, IN, USA., Ravenberg E; Eli Lilly and Company, Indianapolis, IN, USA., Litchfield LM; Eli Lilly and Company, Indianapolis, IN, USA., Smyth L; Eli Lilly and Company, Indianapolis, IN, USA., Wander SA; Massachusetts General Hospital, Harvard University, Boston, MA, USA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Dec 18, pp. JCO2402086. Date of Electronic Publication: 2024 Dec 18.